A detailed history of Yousif Capital Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Yousif Capital Management, LLC holds 108,839 shares of EXEL stock, worth $3.88 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
108,839
Previous 125,346 13.17%
Holding current value
$3.88 Million
Previous $2.82 Million 0.28%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$21.96 - $27.6 $362,493 - $455,593
-16,507 Reduced 13.17%
108,839 $2.82 Million
Q2 2024

Jul 31, 2024

SELL
$20.34 - $23.73 $325,806 - $380,107
-16,018 Reduced 11.33%
125,346 $2.82 Million
Q1 2024

Apr 26, 2024

SELL
$20.17 - $23.93 $170,618 - $202,423
-8,459 Reduced 5.65%
141,364 $3.35 Million
Q4 2023

Feb 01, 2024

SELL
$19.25 - $24.13 $56,595 - $70,942
-2,940 Reduced 1.92%
149,823 $3.59 Million
Q3 2023

Oct 30, 2023

SELL
$19.04 - $22.74 $229,336 - $273,903
-12,045 Reduced 7.31%
152,763 $3.34 Million
Q2 2023

Aug 02, 2023

SELL
$18.17 - $20.48 $81,892 - $92,303
-4,507 Reduced 2.66%
164,808 $3.15 Million
Q1 2023

May 02, 2023

BUY
$16.3 - $19.41 $10,106 - $12,034
620 Added 0.37%
169,315 $3.29 Million
Q4 2022

Jan 09, 2023

BUY
$14.96 - $17.39 $54,813 - $63,716
3,664 Added 2.22%
168,695 $0
Q3 2022

Nov 04, 2022

SELL
$15.68 - $22.27 $236,391 - $335,742
-15,076 Reduced 8.37%
165,031 $2.59 Million
Q2 2022

Aug 01, 2022

BUY
$17.44 - $23.16 $237,358 - $315,207
13,610 Added 8.17%
180,107 $3.75 Million
Q1 2022

May 12, 2022

BUY
$17.03 - $22.67 $32,884 - $43,775
1,931 Added 1.17%
166,497 $3.77 Million
Q4 2021

Jan 31, 2022

BUY
$15.84 - $21.88 $2.61 Million - $3.6 Million
164,566 New
164,566 $3.01 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.